Accessibility Menu
Eastwood Bio-Medical Canada logo

Eastwood Bio-Medical Canada(TSXV) EBM

Market CapCA$66.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+143%
5 Year-42%
1 Year+126%
1 Month-3%
CA$0.97
-2.02%
-0.02Today
Eastwood Bio-Medical Canada last closing stock price
MetricPriceDate
Last closeCAD 0.972026-07-31
Eastwood Bio-Medical Canada stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.02%CAD 0.992026-07-24
1 month-3%CAD 1.002026-06-30
3 month+29.33%CAD 0.752026-05-01
Year to date+19.75%CAD 0.812025-12-31
1 year+125.58%CAD 0.432025-07-29
3 year+14.12%CAD 0.852023-07-28
5 year-42.26%CAD 1.682021-07-30
Since inception+142.5%CAD 0.402014-09-19

Eastwood Bio-Medical Canada Financials at a Glance

Market Cap

CA$66.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$787.78K

Net Income (TTM)

-CA$221.79K

EPS (TTM)

-CA$0.00

P/E Ratio

-303.12

Dividend

CA$0.00

Beta (Volatility)

0.27 (Low)

Price

CA$0.97

Volume

33,430

Open

CA$0.98

Previous Close

CA$0.97

Daily Range

CA$0.96 - CA$1.00

52-Week Range

CA$0.30 - CA$1.10

Estimated Earnings Date

Jun 29, 2026

EBM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eastwood Bio-Medical Canada

Eastwood Bio-Medical Canada Inc. is a Richmond-based company specializing in the marketing and distribution of natural health products. Operating under the Eleotin brand, the company aims to address prevalent metabolic disorders through its diverse product offerings.

Products and Services
  • Eleotin A 700 supports individuals with spleen deficiency and fatigue
  • Eleotin G2000 promotes cardiovascular health
  • Eleotin AL88 serves as a natural laxative
Growth Outlook
  • Expansion into Asian markets is underway, increasing potential customer base
  • Recent product launches have received positive market feedback
  • Focus on metabolic health aligns with growing global health trends
Financial Highlights
  • Q2 2026 revenue of 144978 CAD, showing resilience despite challenges
  • Gross profit margin improved to 72.58% in Q2 2026
  • Operating expenses decreased by 10% compared to previous quarter
Eastwood Bio-Medical Canada Inc. has established itself as a key player in the natural health product sector, particularly with its Eleotin brand. The company’s focus on addressing metabolic disorders positions it well within a growing market. Recent financial data indicates a revenue of 144978 CAD for Q2 2026, reflecting a commitment to maintaining operational resilience. The gross profit margin has shown improvement, reaching 72.58%, which highlights effective cost management strategies. The company is actively pursuing growth opportunities, particularly in Asian markets, which could significantly enhance its customer base. Recent product launches have garnered positive feedback, indicating a strong market presence. Additionally, the focus on metabolic health aligns with global health trends, suggesting a favorable outlook for future growth. Overall, Eastwood Bio-Medical Canada Inc. presents a compelling opportunity for investors interested in the natural health sector, backed by a solid product portfolio and a strategic growth plan.
AI Generated • Jul 26, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Youngsoo Kim, PhD

Website

www.eleotincanada.com

Headquarters

Richmond, BC V6X 3Z6, CA

EBM Financials

Key Financial Metrics (TTM)

Gross Margin

63.18%

Operating Margin

-58.21%

Net Income Margin

-62.98%

Return on Equity

96.32%

Return on Capital

N/A

Return on Assets

-111.75%

Earnings Yield

-0.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$66.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.89M

Volume

33.43K

Avg. Volume

8.55K

Financials (TTM)

Gross Profit

CA$553.47K

Operating Income

-CA$261.91K

EBITDA

-CA$241.01K

Operating Cash Flow

CA$3.63K

Capital Expenditure

CA$0.00

Free Cash Flow

CA$3.63K

Cash & ST Invst.

CA$9.04K

Total Debt

CA$67.98K

Eastwood Bio-Medical Canada Performance Analysis

Eastwood Bio-Medical Canada annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31CAD 1,299,76332.5%
20232023-10-31CAD 867,936-33.2%
20242024-10-31CAD 702,076-19.1%
20252025-10-31CAD 782,08011.4%
Eastwood Bio-Medical Canada sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-3163.4%
Q42025-10-31191.0%
Q12026-01-31-58.3%
Q22026-04-30-4.8%
Eastwood Bio-Medical Canada annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31CAD -0.00-75.0%
20232023-10-31CAD -0.01259.1%
20242024-10-31CAD -0.01-16.5%
20252025-10-31CAD -0.00-27.3%
Eastwood Bio-Medical Canada sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-3165.2%
Q42025-10-31-37.5%
Q12026-01-31127.3%
Q22026-04-30-433.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$144.98K

+88.8%

Gross Profit

CA$105.23K

+181.3%

Gross Margin

72.58%

N/A

Market Cap

CA$66.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$22.27M

N/A

Employees

3

N/A

Net Income

-CA$66.38K

+57.7%

EBITDA

-CA$53.89K

+65.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$9.04K

-52.3%

Total Debt

CA$67.98K

-15.2%

Accounts Receivable

CA$90.34K

+199.2%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$67.98K

-15.2%

Return on Assets

-1.12%

N/A

Return on Invested Capital

60.09%

N/A

Free Cash Flow

CA$2.26K

-82.5%

Operating Cash Flow

CA$2.26K

-82.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SWP.TOSwiss Water Decaffeinated Coffee Inc.
CA$5.57-1.42%
BU.TOBurcon NutraScience Corporation
CA$1.80-3.23%
BR.TOBig Rock Brewery Inc.
CA$0.64+1.59%
GCL.TOColabor Group Inc.
CA$0.04+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.38-0.05%
NVDANvidia
$207.26+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.84+0.07%
INTCIntel
$90.68+0.01%

Questions About EBM

What is the current price of Eastwood Bio-Medical Canada?

Eastwood Bio-Medical Canada is trading at CA$0.97 per share.

What is the 52-week range for Eastwood Bio-Medical Canada?

Over the past 52 weeks, Eastwood Bio-Medical Canada has traded between CA$0.30 and CA$1.10.

How much debt does Eastwood Bio-Medical Canada have?

As of the most recent reporting period, Eastwood Bio-Medical Canada reported total debt of CA$67.98K.

How much cash does Eastwood Bio-Medical Canada have on hand?

Eastwood Bio-Medical Canada reported CA$9.04K in cash and cash equivalents in its most recent financial results.

What is Eastwood Bio-Medical Canada’s dividend yield?

Eastwood Bio-Medical Canada does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services